Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ThermoGenesis Holdings Inc is a medical devices business based in the US. ThermoGenesis shares (THMO) are listed on the NASDAQ and all prices are listed in US Dollars. ThermoGenesis employs 40 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $1.00 |
|---|---|
| 52-week range | $0.95 - $4.45 |
| 50-day moving average | $1.23 |
| 200-day moving average | $2.08 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.14 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1 from 2022-01-20
| 1 week (2022-01-14) | 1 |
|---|---|
| 1 month (2021-12-22) | -12.28% |
| 3 months (2021-10-22) | -37.50% |
| 6 months (2021-07-22) | -58.51% |
| 1 year (2021-01-22) | -62.26% |
|---|---|
| 2 years (2020-01-22) | -79.80% |
| 3 years (2019-01-22) | 207.60% |
| 5 years (2017-01-20) | 2.76 |
| Revenue TTM | $8.8 million |
|---|---|
| Gross profit TTM | $1.3 million |
| Return on assets TTM | -22.85% |
| Return on equity TTM | -252.23% |
| Profit margin | -131.18% |
| Book value | $0.54 |
| Market capitalisation | $12 million |
TTM: trailing 12 months
We're not expecting ThermoGenesis to pay a dividend over the next 12 months.
ThermoGenesis's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ThermoGenesis shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for ThermoGenesis shares which in turn could have impacted ThermoGenesis's share price.
Over the last 12 months, ThermoGenesis's shares have ranged in value from as little as $0.95 up to $4.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ThermoGenesis's is 2.9605. This would suggest that ThermoGenesis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem, and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.